Mark Johnson is professor of experimental psychology and head of the psychology department at the University of Cambridge in the United Kingdom.
Mark Johnson
Professor
Birkbeck University of London
From this contributor
Autism may arise from brain’s response to early disturbances
Autism is not a developmental disorder, but rather the brain’s adaptive response to early genetic or environmental disturbances, says Mark Johnson.
Autism may arise from brain’s response to early disturbances
By
Mark Johnson
18 August 2015 | 6 min read
Executive confusion
Among siblings of children with autism, those with better prefrontal cortex functioning — observable as relatively strong executive functions for their age — are better able to compensate for atypicalities in other brain systems early in life, and are therefore less likely to receive a diagnosis of autism later in their development, argues Mark H. Johnson.
Explore more from The Transmitter
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
By
Lauren Schneider
4 February 2026 | 7 min read
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
By
Claudia López Lloreda
3 February 2026 | 4 min read
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
By
Calli McMurray
3 February 2026 | 5 min read